This article summarized the latest R&D progress of Lidocaine hydrochloride, the Mechanism of Action for Lidocaine hydrochloride, and the drug target R&D trends for Lidocaine hydrochloride.

Harpoon Therapeutics, Inc. has shared the interim outcomes of its Phase 1 clinical trial on the effect of single-agent HPN217 in treating relapsed or refractory multiple myeloma, focused on target dose groups from 2.15 to 12mg.

This article summarized the latest R&D progress of Letermovir, the Mechanism of Action for Letermovir, and the drug target R&D trends for Letermovir.

Akeso revealed that the FDA has approved their IND for CD47 Monoclonal Antibody (AK117) combined with Azacitidine for treating Myelodysplastic Syndromes.

This article summarized the latest R&D progress of Olopatadine hydrochloride, the Mechanism of Action for Olopatadine hydrochloride, and the drug target R&D trends for Olopatadine hydrochloride.

Adcentrx Therapeutics reports the initial dosing of a patient in the Phase 1a/b trial of ADRX-0706, an innovative ADC targeting Nectin-4, aimed to treat advanced solid tumors.

This article summarized the latest R&D progress of Ixekizumab, the Mechanism of Action for Ixekizumab, and the drug target R&D trends for Ixekizumab.

Kallyope, Inc. has commenced its Phase 2 experiment to assess K-757 and K-833.

This article summarized the latest R&D progress of Inclisiran, the Mechanism of Action for Inclisiran, and the drug target R&D trends for Inclisiran.

A new research indicates that Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, elicits robust and long-lasting immunity in lab animals.

This article summarized the latest R&D progress of Heparin sodium, the Mechanism of Action for Heparin sodium, and the drug target R&D trends for Heparin sodium.

Takeda announced U.S. FDA approval for ENTYVIO®(vedolizumab) subcutaneous delivery as a maintenance treatment for moderate to severe ulcerative colitis in adults, after initial intravenous therapy.